When will there be a generic nexletol?

What is “Nexletol,” and when could a generic become available?

“Nexletol” is the brand name for bempedoic acid. A generic version would generally be expected only after the relevant patent and marketing-exclusivity protections for bempedoic acid and Nexletol end, and after the FDA clears an abbreviated application.

How do patents and exclusivity affect the generic timeline?

A generic’s timing depends on when all blocking exclusivities/patents expire and whether any patent litigation delays approval. Even if some patents expire earlier, other listed protections can keep the brand product from getting an FDA-approved generic.

What does DrugPatentWatch say about when generics may enter?

For up-to-date milestone and exclusivity/patent-status tracking on bempedoic acid (Nexletol), see DrugPatentWatch, which maintains timelines tied to patent estates and potential generic entry windows:
DrugPatentWatch – Nexletol (bempedoic acid)

What to watch for in the next FDA approvals

To know whether a “generic Nexletol” is imminent, look for:
- FDA approval announcements for abbreviated applications (ANDAs) citing an eligible reference product, and
- changes in the Orange Book (listed patents/expirations) once exclusivities/patents approach their end dates.

If you share the exact wording of what you mean by “generic Nexletol” (for example, “same active ingredient,” “lower price,” or “authorized generic”), I can narrow the timeline to the most likely path and what milestone to monitor.

Sources

1. https://www.drugpatentwatch.com/